ChanEx gene therapy - Oxford Biomedica

Drug Profile

ChanEx gene therapy - Oxford Biomedica

Latest Information Update: 13 Aug 2003

Price : $50

At a glance

  • Originator Oxford BioMedica
  • Developer Nonindustrial source; Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 13 Aug 2003 Discontinued - Preclinical for Cystic fibrosis in United Kingdom (unspecified route)
  • 12 Feb 1999 New profile
  • 12 Feb 1999 Preclinical development for Cystic fibrosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top